NLRP3 and epilepsy: These findings suggest that ADSC-Exos offer neuroprotective effects in TLE, by modulating NLRP3-dependent pyroptosis, pointing to a promising therapeutic approach targeting neuroinflammatory mechanisms in epilepsy.